250 related articles for article (PubMed ID: 22205997)
21. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the testis and epididymis in mouse models of human Tay Sachs and Sandhoff diseases and partial determination of accumulated gangliosides.
Trasler J; Saberi F; Somani IH; Adamali HI; Huang JQ; Fortunato SR; Ritter G; Gu M; Aebersold R; Gravel RA; Hermo L
Endocrinology; 1998 Jul; 139(7):3280-8. PubMed ID: 9645704
[TBL] [Abstract][Full Text] [Related]
23. Tay-Sachs disease brain cells in culture: mobilization of stored GM2 after concanavalin A-mediated uptake of hexosaminidase A.
Hoffman LM; Brooks SE; Amsterdam D; Oropello J; Schneck L
J Neurosci Res; 1980; 5(5):413-7. PubMed ID: 7441795
[TBL] [Abstract][Full Text] [Related]
24. Sandhoff disease: a prevalent form of infantile GM2 gangliosidosis in Lebanon.
Der Kaloustian VM; Khoury MJ; Hallal R; Idriss ZH; Deeb ME; Wakid NW; Haddad FS
Am J Hum Genet; 1981 Jan; 33(1):85-9. PubMed ID: 7468596
[TBL] [Abstract][Full Text] [Related]
25. GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.
Raghavan SS; Krusell A; Krusell J; Lyerla TA; Kolodny EH
Am J Hum Genet; 1985 Nov; 37(6):1071-82. PubMed ID: 2934978
[TBL] [Abstract][Full Text] [Related]
26. [Biosynthesis and biodegradation of GM2 ganglioside].
Hirabayashi Y; Kasakura H; Matsumoto M
Tanpakushitsu Kakusan Koso; 1984 Sep; 29(9):708-22. PubMed ID: 6240072
[No Abstract] [Full Text] [Related]
27. Epstein-Barr virus transformed lymphoid cell lines as a new model system in culture for the study of GM2-gangliosidoses: Tay-Sachs and Sandhoff diseases.
Maret A; Salvayre R; Negre A; Bes JC; Douste-Blazy L
Biol Cell; 1985; 53(3):293-6. PubMed ID: 2990625
[TBL] [Abstract][Full Text] [Related]
28. GM2-ganglioside metabolism in cultured human skin fibroblasts: unambiguous diagnosis of GM2-gangliosidosis.
Raghavan S; Krusell A; Lyerla TA; Bremer EG; Kolodny EH
Biochim Biophys Acta; 1985 Apr; 834(2):238-48. PubMed ID: 3995063
[TBL] [Abstract][Full Text] [Related]
29. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
[TBL] [Abstract][Full Text] [Related]
30. Enzyme replacement treatment for Tay-Sachs disease brain cells in culture utilizing concanavalin A-mediated hexosaminidase A uptake: biochemical and morphological evidence of GM2 mobilization.
Brooks SE; Hoffman LM; Adachi M; Amsterdam D; Schneck L
Acta Neuropathol; 1980; 50(1):9-17. PubMed ID: 7376831
[TBL] [Abstract][Full Text] [Related]
31. The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A.
Meier EM; Schwarzmann G; Fürst W; Sandhoff K
J Biol Chem; 1991 Jan; 266(3):1879-87. PubMed ID: 1824846
[TBL] [Abstract][Full Text] [Related]
32. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
[TBL] [Abstract][Full Text] [Related]
33. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
34. Biology and potential strategies for the treatment of GM2 gangliosidoses.
Chavany C; Jendoubi M
Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
[TBL] [Abstract][Full Text] [Related]
35. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
[TBL] [Abstract][Full Text] [Related]
36. Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model.
Martino S; Cavalieri C; Emiliani C; Dolcetta D; Cusella De Angelis MG; Chigorno V; Severini GM; Sandhoff K; Bordignon C; Sonnino S; Orlacchio A
Neurochem Res; 2002 Aug; 27(7-8):793-800. PubMed ID: 12374215
[TBL] [Abstract][Full Text] [Related]
37. Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.
Inui K; Grebner EE; Jackson LG; Wenger DA
Am J Hum Genet; 1983 Jul; 35(4):551-64. PubMed ID: 6224417
[TBL] [Abstract][Full Text] [Related]
38. GM2 gangliosidoses: a review of cases confirmed by beta-N-acetylhexosaminidase assay.
Christopher R; Rangaswamy GR; Shetty KT
Indian J Pediatr; 1995; 62(4):479-83. PubMed ID: 10829909
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
40. Serum beta-hexosaminidases in pregnancy.
Lowden JA
Clin Chim Acta; 1979 May; 93(3):409-17. PubMed ID: 445857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
